(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 55.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Plus Therapeutics's revenue in 2025 is $5,258,000.On average, 6 Wall Street analysts forecast PSTV's revenue for 2025 to be $879,683,381, with the lowest PSTV revenue forecast at $565,657,990, and the highest PSTV revenue forecast at $1,356,149,915. On average, 6 Wall Street analysts forecast PSTV's revenue for 2026 to be $889,028,557, with the lowest PSTV revenue forecast at $538,721,896, and the highest PSTV revenue forecast at $1,748,097,580.
In 2027, PSTV is forecast to generate $3,166,502,856 in revenue, with the lowest revenue forecast at $2,325,162,182 and the highest revenue forecast at $4,040,414,217.